Treatment Uses Reduced-Intensity Preconditioning to Enhance Its Global Transportability
After over a decade of preclinical research and development, a new gene therapy treatment for sickle cell anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.
Preliminary data from a pilot Phase 1-2 clinical trial testing the gene-addition therapy were presented Dec. 3 at the American Society of Hematology’s (ASH) annual meeting in San Diego by principal investigator Punam Malik, MD. She is a physician-scientist at the Cincinnati Children’s Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center. Malik called the data promising.
“One year after treatment of our first patient, and six months after treatment of our second patient, both have seen a remarkable improvement in the quality of life due to remarkable reduction in disease symptoms. This includes near elimination of chronic pain and sickling events and improved anemia,” Malik said. “Although it’s still early post-treatment, these preliminary results are quite promising. If sustained this therapy will provide a transportable, safe and feasible gene therapy for all SCA patients.”
SCA is a painful, inherited disease where blood cells become sickle-shaped and stuck in the vascular system. It can damage vital organs and cause death.
How the Therapy Works
The gene therapy developed by Cincinnati Children’s uses a modified gamma globin lentivirus vector to transfer a healthy fetal hemoglobin gene into a patient’s blood stem cells (hematopoietic stem cells, HSC). The lentivirus is modified so it does not cause illness.
The therapy comes from the observation that some adults never stop producing fetal hemoglobin (HbF). This prevents red blood cell sickling when sufficient quantities of HbF are present in the body. Normally, the fetal hemoglobin gene switches off shortly after birth. The new gene therapy approach designed by Malik and team places a fetal hemoglobin gene in the bone marrow cells that cannot switch off.
Cells are collected earlier from the SCA patient and genetically reprogrammed in a clean lab facility with the modified lentivirus vector. Then the patient’s bone marrow is preconditioned with one low-dose of chemotherapy, after which the gene-corrected cells are infused back into the patient. Patients recover their blood counts within a week to 10 days and recover from the chemotherapy effects by two weeks, Malik said.
A key feature of the treatment regimen is the reduced-intensity preconditioning for patients receiving the therapy for SCA. The method is less toxic and expensive than myeloablative preconditioning normally used in bone marrow transplants, according to the researchers.
Myeloablative conditioning uses high-intensity chemotherapy to prepare a transplant patient’s bone marrow for healthy gene-corrected blood stem cells (HSCs). This typically results in low blood counts and other side effects. These can include severe infections and long stays in transplant units for one or two months.
This means transplants using myeloablative conditioning have to be performed at large and sophisticated medical centers in developed parts of the world. Malik said this limits access to people in underdeveloped regions where SCA is more common, like Africa, India, the Caribbean and South America.
Reaching High-Need Regions
One goal for Malik and her colleagues is that their therapy’s reduced intensity conditioning will allow it to be offered at hospitals in places like Central Africa and other underdeveloped regions of the world.
SCA affects more than 90,000 people in the United States, and millions of people worldwide have the disease, according to the researchers.
Malik said additional data from the study will tell investigators of the consistent and long-term clinical benefit of this therapy to patients with severe SCA. The trial is scheduled to treat up to 10 patients with SCA. Preclinical studies by the research team suggested the treatment allows the body to produce normal red blood cells instead of the sickle-shaped cells that define the inherited disorder.
Improved Quality of Life
Both adult patients included in the ASH presentation are 35 and 25 years old who, respectively, had gene transfer therapy 15 and 12 months ago. In the year and a half prior to receiving gene-correction therapy, both patients had more than a dozen acute sickle events per year, according to Malik. These included acute chest and pain crises, chronic pain, and required the ongoing use of oral or injectable opioids on a regular basis.
Investigators report that one year following therapy, the first patient no longer requires daily oral opioids for chronic pain and has had one acute sickle cell event. The second patient no longer uses oral opioids and has no vaso-occlusive events, where blood cells become stuck in the vascular system.
The Latest on: Sickle cell anemia
via Google News
The Latest on: Sickle cell anemia
- Oregon Parents Push Bill To Screen Newborns For More Diseases on April 17, 2019 at 2:11 pm
There, they test for everything from sickle cell anemia to cystic fibrosis. But Oregon checks for fewer diseases in newborns than recommended by the federal government. Now parents with children dying ... […]
- Author Jamie Metzl says the "genetic revolution" could threaten national security on April 17, 2019 at 3:58 am
Could gene therapy cure sickle cell anemia? Recent advances in reproductive technologies and genetic screening hold tremendous promise for the elimination of harmful inherited diseases, but they also ... […]
- 8-Year-Old’s Bone Marrow Donation Cures His Siblings of Sickle Cell on April 16, 2019 at 5:30 pm
Sickle cell is an inherited form of anemia that mostly affects people of African descent. It can be treated, but bone marrow transplants are the only known cure and finding matching donors is a ... […]
- ‘Sickle cell warrior’ encourages blood donations on April 15, 2019 at 8:18 pm
Sickle cell anemia is an inherited blood disorder condition that causes abnormal blood cells to stick together and block blood flow and oxygen, causing complications. Williams was diagnosed with ... […]
- NFL Broadcaster Solomon Wilcots and Emmaus Life Sciences Kick Off "Sideline Sickle Cell" Campaign during National Minority Health Month on April 15, 2019 at 1:08 pm
Its lead product, Endari, demonstrated positive clinical results in the completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia and has received U.S. FDA approval. […]
- Sickle Cell and disability on April 12, 2019 at 4:05 pm
The benefits for Sickle Cell victims under any disability law ... Most importantly, yams fight against anaemia with its high iron content. All the benefits found in yams promote the production ... […]
- Blood Drive Series For 11-Month-Old With Sickle Cell Anemia on April 12, 2019 at 3:39 pm
The family of 11-month-old Sickle Cell patient Christian Olivia is partnering with the New York Blood Center to host a series of blood drives in time for Olivia's first birthday on Saturday. […]
- Cancer patients and those with anemia should not be denied opioids, says CDC on April 11, 2019 at 5:44 am
The U.S. Centers for Disease Control and Prevention (CDC) has issued a letter clarifying that people suffering from severe pain caused by cancer or sickle-cell anemia should not be denied ... […]
- Motorcycle ride to support Sickle Cell charities in RVA on April 10, 2019 at 10:49 am
The goal of the Unity Ride is to heighten awareness of Sickle Cell Anemia and raise money to fund programs which will assist your friends and neighbors suffering from this disease. The tax deductible ... […]
via Bing News